Mbange Aristid Ekollo, Kaba Djiba, Diouara Abou Abdallah Malick, Diop-Ndiaye Halimatou, Ngom-Ngueye Ndeye Fatou, Dieng Ahmed, Lo Seynabou, Toure Kine Ndiaye, Fall Mamadou, Mbacham Wilfred Fon, Diallo Mariama Sadjo, Cisse Mohamed, Mboup Souleymane, Kane Coumba Toure
Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Diamniadio, Sénégal.
The Biotechnology center, Department of Biochemistry, University of Yaoundé I, Yaoundé, Cameroon.
BMC Res Notes. 2018 Oct 12;11(1):723. doi: 10.1186/s13104-018-3804-9.
Disruption in HIV care provision may enhance the development and spread of drug resistance due to inadequate antiretroviral therapy. This study thus determined the prevalence of HIV-1 transmitted drug resistance (TDR) in settings of decentralized therapy and care in Senegal and, the Ebola outbreak in Guinea. Antiretroviral-naïve patients were enrolled following a modified WHO TDR Threshold Survey method, implemented in Senegal (January-March 2015) and Guinea (August-September 2015). Plasma and dried blood spots specimens, respectively from Senegalese (n = 69) and Guinean (n = 50) patients, were collected for direct sequencing of HIV-1 pol genes. The Stanford Calibrated Population Resistance program v6.0 was used for Surveillance Drug Resistance Mutations (SDRMs).
Genotyping was successful from 54/69 (78.2%) and 31/50 (62.0%) isolates. In Senegal, TDR prevalence was 0% (mean duration since HIV diagnosis 4.08 ± 3.53 years). In Guinea, two patients exhibited SDRMs M184V (NRTI), T215F (TAM) and, G190A (NNRTI), respectively. TDR prevalence at this second site, however, could not be ascertained because of low sample size. Phylogenetic inference confirmed CRF02_AG predominance in Senegal (62.96%) and Guinea (77.42%). TDR prevalence in Senegal remains extremely low suggesting improved control measures. Continuous surveillance in both settings is mandatory and, should be done closest to diagnosis/transmission time and with larger sample size.
由于抗逆转录病毒疗法不足，艾滋病毒治疗服务中断可能会加速耐药性的产生和传播。因此，本研究确定了在塞内加尔分散治疗与护理环境以及几内亚埃博拉疫情背景下，HIV-1传播耐药性（TDR）的流行情况。按照经修改的世卫组织TDR阈值调查方法，在塞内加尔（2015年1月至3月）和几内亚（2015年8月至9月）招募了未接受过抗逆转录病毒治疗的患者。分别收集了塞内加尔（n = 69）和几内亚（n = 50）患者的血浆和干血斑样本，用于HIV-1 pol基因的直接测序。使用斯坦福校准人群耐药性程序v6.0检测监测耐药性突变（SDRM）。
54/69（78.2%）和31/50（62.0%）的分离株基因分型成功。在塞内加尔，TDR流行率为0%（自诊断为艾滋病毒以来的平均时长为4.08±3.53年）。在几内亚，两名患者分别出现了SDRM M184V（核苷类逆转录酶抑制剂）、T215F（胸苷酸合成酶）和G190A（非核苷类逆转录酶抑制剂）。然而，由于样本量小，该地区的TDR流行率无法确定。系统发育推断证实CRF02_AG在塞内加尔（62.96%）和几内亚（77.42%）占主导地位。塞内加尔的TDR流行率仍然极低，表明控制措施有所改善。在这两个地区都必须持续进行监测，且应在最接近诊断/传播时间时进行，同时增加样本量。
